Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes for Both |
| |
| Institution: | 1. From the University of Colorado Anschutz Medical Campus, Aurora, Colorado.;1. From the Section of Endocrinology, VA Nebraska-Western Iowa Healthcare System (NWIHCS), Omaha, Nebraska;2. University of Nebraska Medical Center (UNMC), Omaha, Nebraska;3. Creighton University Medical Center, Omaha, Nebraska.;4. Creighton Division of Clinical Research and Evaluative Sciences, Omaha, Nebraska.;1. Servicio de Medicina Interna, Hospital Clínico Universitario “Lozano Blesa”, Zaragoza, Spain;2. Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Facultad de Medicina, Universidad de Zaragoza, Spain;3. Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Spain;1. From the University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin.;2. Department of Medicine, Madison, Wisconsin.;3. Department of Pathology and Laboratory Medicine, Madison, Wisconsin. |
| |
| Abstract: | Objective: The purpose of this review is to expose the surprising prevalence of diabetes-related complications in people with persistent prediabetes, and hence, to expand the paradigm of diabetes prevention to include the prevention of complications related to both hyperglycemia and obesity.Methods: Published literature was reviewed.Results: Approximately 84 million Americans have prediabetes, 85% of whom are overweight or obese. Although the incidence of diabetes-related complications is lower in people with prediabetes versus those with type 2 diabetes, the overall prevalence is virtually identical. Furthermore, many people with prediabetes not only suffer from the complications related to hyperglycemia, they also experience complications of obesity. Treating obesity as a disease has the potential to prevent complications of both hyperglycemia and obesity. Emerging data reveal the untapped potential for clinicians to enhance the effectiveness of anti-obesity medications through a mindful health care delivery style. This involves an understanding and ethical utilization of the placebo effect in conjunction with active medical therapy. This approach is not intended to mislead patients but rather to activate neurocircuitry that synergizes with the central action of the approved anti-obesity medications to potentiate weight loss.Conclusion: Mindful administration of anti-obesity medications has the potential for widespread health benefits in people with obesity and prediabetes.Abbreviations: ADA = American Diabetes Association; DPP = Diabetes Prevention Program; CVD = cardiovascular disease |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
